noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Prospect Capital Corporation

Other Report or Announcement
Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3[...]
Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3[...]

Healthcare

Haemonetics Corporation

08/18/2026 | Press release | Distributed by Public on 08/18/2026 04:05

Regulation FD Disclosure (Form 8-K)

Item 7.01 Regulation FD Disclosure

On August 14, 2026, Haemonetics Corporation (the "Company") entered into a supply agreement with CSL Plasma Inc. ("CSL") pursuant to which CSL may utilize the Company's NexSys PCS® devices with Persona® PLUS technology and purchase related disposables in the United States. The supply agreement is non-exclusive and does not contain minimum purchase commitments.

Haemonetics anticipates CSL to transition a portion of its U.S. plasma collection centers to the Company's devices and disposables, but the scope and timing of implementation have not yet been determined. Accordingly, the Company is not updating its previously issued fiscal 2027 guidance at this time. The Company expects to provide an update regarding the anticipated impact of the agreement on its fiscal 2027 financial results in connection with its second fiscal quarter earnings call in November 2026.

The foregoing information in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Haemonetics Corporation published this content on August 18, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 18, 2026 at 10:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]